Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype

BACKGROUND: B-raf inhibitors (BRAFi) are effective for BRAF-mutated papillary (PTC) and anaplastic (ATC) thyroid carcinomas, although acquired resistance impairs tumour cells’ sensitivity and/or limits drug efficacy. Targeting metabolic vulnerabilities is emerging as powerful approach in cancer. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Aprile, Marianna, Cataldi, Simona, Perfetto, Caterina, Federico, Antonio, Ciccodicola, Alfredo, Costa, Valerio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338540/
https://www.ncbi.nlm.nih.gov/pubmed/37198319
http://dx.doi.org/10.1038/s41416-023-02282-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338540/
https://www.ncbi.nlm.nih.gov/pubmed/37198319
http://dx.doi.org/10.1038/s41416-023-02282-2

Ejemplares similares